Also, whens the next bit of good news coming out from achn? 2-3 months? Maybe? What is it and when? Move on smelk, check out ziop after their secondary, they are kicking achns #$%$
Lol, i covered at 10.90 and may initiate a new short around 13.5. And btw you told me your call strategy and if you told me the truth , you are currently well out of the $. Good luck, you know a lot o those guys who got shares at 10.25 are flippin them now for an easy quick short term profit. They are also free to short knowing they can cover w those 10.25 shares. Its gonna be a slog here at 12.24, not worth anyones time imo
One? I would think if management was at all confident in a buyout was coming , insiders would be backing up the truck! Are they? Look for yourself........Did achn management buy a single share in the latest secondary? We shall see
Sentiment: Strong Buy
Did you call achn IR to get this circle jerk info/justification? Lol just like you emailed or called about the 700 mg dose? Too funny
Another supposedly prime suitor passes on achn. BMY buys Flexus for 1.35 bill. Lol i guess achn is not a top priority. Lol. I guess its not for gilead, abbvie, etc etc either. Keep waiting but dont hold your breath
omg that is hilarious! how was he "absolutely sure" if he had never dosed 3423 at 700 mgs before? he wasnt sure you clown, thats why they run the P1-3 studies before the NDA. and i got news for you, sometimes tox shows up years after the nda and the drug had been on the market. so how exactly was he "absolutely sure" again Pumper? lol
Thats why they actually have to run P2 and P3 trials lol quote from achillions own website:
"ACH-3422 is an investigational compound. Its safety and efficacy have not been established. (Updated February 2015) "
look it up yourself.
I guess igober is a stupid basher:
Bergycb, I dont know what happened in that episode as i remember too, magnam said the IR person said to him they didnt tested 700mg and they did. i believe magnam has not explainded it.
For 700 mgs i only see mention of 6 patients, i see no mention that 100 patients got the highest dose, read below
Interim study results were also released for ACH-3422, demonstrating that the compound achieved proof of concept in a Phase 1 trial of patients with treatment-naive genotype 1 HCV. The Phase 1 trial is a randomized, double-blind, placebo-controlled trial evaluating the safety, tolerability, pharmacokinetics and antiviral activity of ACH-3422. The trial features escalating doses of ACH-3422 ranging from 50 mg to 700 mg in healthy volunteers in single ascending dose cohorts, followed by 14-day multiple ascending dose cohorts. All doses proved to be well-tolerated, with no significant adverse events. The 700 mg dose group saw mean maximal reduction in HCV viral RNA load of 4.8 log10 IU/ml within 14 days, with three out of six patients achieving undetectable HCV RNA. ACH-3422's pharmacodynamic characteristics proved capable of providing sustained antiviral activity, which resulted in an additional 1.4 log10 reduction in HCV RNA between day seven and day 14 of dosing.
Uridine yes but there are 3 parts to a nuc. The nucleotide, the prodrug portion and the sugar moiety. Look up the vertex structure that had tox and 3422 and decide for yourself. What was the highest does of that 100 patient P1 study? Was it 700 mg for 2 weeks? I cant find that info. Finally i will leave you with this quote from achillions own website:
ACH-3422 is an investigational compound. Its safety and efficacy have not been established. (Updated February 2015)
This is one of the most pathetic posts i have read in terms of scientific interpretation. first, the above poster is the same poster who did not know the diff between issued and published when it came to the 3422 patent. Second this poster claims that he emailed achn IR and asked if 3422 had been dosed at 700 mgs before the results came out., and the poster claimed that achn said no they did not up the dose to 700 mg. Then achn released the data and in fact they had upped the dose to 700 mg to achieve efficacy.
Now in terms of toxicity, 3422 is basically a hybrid between sovaldi and a vertex drug w some deuteriums also present. Dont take my word for this or mags word, look it up yourself, the sovaldi structure, the vertex structure and 3422. Educate yourself. And the fact is the vertex nuc wound up w tox. Again look it up yourself. And 3422 is a hybrid of the vertex nuc. Not the best news. The addition of deuterium alone could change the tox profile of 3422 compared to sovaldi or vertex nuc. Any decent clinician would tell you this but of course mag doesnt mention it rather conveinantly.
The only thing a clinician would say w any confidence is that 3422 did not cause any tox in the 6 SIX patients examined. What happens when you dose dozens (if not hundreds) of NEW patients w diff nationalities and genetic makeup from the first six patients remains to be seen. A clinician would tell you tox could show up in the new patients or maybe not. Anybody who says otherwise is just a shameless pumper, buyer beware. Anyone who would lie about the 3422 700 mg dose has zero credibility. I have no position in this stock now but may initiate a short at 13.5
Health Canada has rejected fitx. No revenue yet 40 mill market cap. Buy EAPH, only 10 mill market cap and 32 mill in revenue coming in. Look it up : Easton Pharma and Medicated Markets. And EAPH unlike fitx has a MMPR license with Health Canada still pending
Dont get your hopes up to high, tweed only took in about 1 mill in revenue last year and they have a 80 mill $ market cap. Based on EAPH's current market cap if they guide to $400k in revenue for the year that would be pretty great